Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hydronephrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Hydronephrosis. Displaying page 1 of 1.
    EudraCT Number: 2007-000983-26 Sponsor Protocol Number: EFC6269 Start Date*: Information not available in EudraCT
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: 12-week, multicenter, open-label, non-comparative study to investigate pharmacodynamic and safety of alfuzosin 0.2 mg/kg/day in the treatment of children and adolescents 2 - 16 years of age with hy...
    Medical condition: Children with voiding dysfunction of neuropathic etiology
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047685 Voiding difficulty LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) EE (Completed) BG (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-003906-81 Sponsor Protocol Number: A7-2 Start Date*: 2005-01-14
    Sponsor Name:Oncology Institute of Vilnius University
    Full Title: Chemoradiation with once weekly gemcitabine for invasive bladder cancer
    Medical condition: Invasive transitional cell bladder cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001823-38 Sponsor Protocol Number: AB65/18 Start Date*: 2018-11-26
    Sponsor Name:Technische Universität München, Fakultät für Medizin vertreten durch den Dekan
    Full Title: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urot...
    Medical condition: Locally advanced urothelial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001429-41 Sponsor Protocol Number: ML39568 Start Date*: 2017-12-20
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
    Full Title: “TOCIlizumab for difficult-to-treat RETroperitoneal fibrosis. TOCIRET Trial”
    Medical condition: idiopathic retroperitoneal fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10021244 Idiopathic retroperitoneal fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004417-13 Sponsor Protocol Number: CHUBX2018/65 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Bordeaux
    Full Title: PROSPECTIVE RANDOMIZED CLINICAL TRIAL OF EARLY OXYBUTININ TREATMENT FOR BOYS WITH POSTERIOR URETHRAL VALVES
    Medical condition: POSTERIOR URETHRAL VALVES
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002803-81 Sponsor Protocol Number: TREX Start Date*: 2020-04-03
    Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI
    Full Title: Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children
    Medical condition: Children under the age of 2 years having surgery lasting at least 2 hours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10018060 General anaesthesia PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000097-56 Sponsor Protocol Number: HOVON110 Start Date*: 2013-06-11
    Sponsor Name:HOVON Foundation
    Full Title: ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma A HOVON/GLSG/NCRI study
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016905 Follicle centre lymphoma, follicular grade I, II, III recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-006433-13 Sponsor Protocol Number: TNG-CL008 Start Date*: 2008-06-11
    Sponsor Name:Tengion Inc.
    Full Title: An open-label, multicentre study of augmentation cystoplasty using an autologous Neo-Bladder construct in subjects with spina bifida.
    Medical condition: Neurogenic bladder secondary to spina bifida
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder LLT
    9.1 10041524 Spina bifida LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001028-32 Sponsor Protocol Number: CIVI/2018/NH-01 Start Date*: 2020-09-09
    Sponsor Name:CHU DE NIMES
    Full Title: Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable,...
    Medical condition: The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003048-52 Sponsor Protocol Number: 527.51 Start Date*: 2007-10-29
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bla...
    Medical condition: Neurogenic Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029279 Neurogenic bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003517-42 Sponsor Protocol Number: SPI-1012 Start Date*: 2011-11-23
    Sponsor Name:Spectrum Pharmaceuticals, Inc
    Full Title: A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patie...
    Medical condition: The medical condition under investigation is noninvasive bladder cancer in patients undergoing transurethral resection of bladder tumor/tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005007 Bladder cancer stage 0, without cancer in situ PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA